B9991040- A Phase 1B/2 Study To Evaluate Safety And Clinical Activity Of Avelumab In Combination With Bempegaldesleukin (Nktr-214) With Or Without Talazoparib Or Enzalutamide In Participants With Locally Advanced Or Metastatic Solid Tumor
Posted Date: Apr 23, 2020
- Investigator: Shuchi Gulati
- Specialties: Cancer, Oncology
- Type of Study: Drug
The goal for phase 1 is To assess the dose-limiting toxicity (DLT) rate of avelumab in combination with bempegaldesleukin (NKTR-214) and talazoparib or enzalutamide in order to determine the recommended Phase 2 dose (RP2D) for the combinations.
Criteria:
To Be Eligible: Must Have Diagnosis Of Solid Tumor, Progressive Disease At Time Of Enrollment, Adequate Organ Function, No Prior Treatment For Study Cancer
Keywords:
Phase 1, Oncology
For More Information:
Uc Cancer Center
513-584-7698
cancer@uchealth.com